ArticleCurrent pharmaceutical design2025
3',4'-Dihydroxy Flavonol (DiOHF) Exerting a Positive Effect on Neurogenesis and Retinal Damage in Experimental Brain Ischemia-Reperfusion of Rats.
Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuroprotective effect of 3',4'-dihydroxyflavonol on blood-brain barrier ıntegrity and matrix remodeling in rats with transient bilateral carotid occlusion-ınduced ıschemia-reperfusion.Journal of bioenergetics and biomembranes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBrain ischemia-reperfusion can cause serious and irreversible health problems. Recent studies have suggested that certain flavonoids may help stabilize the correctly folded structure of the visual photoreceptor protein rhodopsin and offset the deleterious effect of retinitis pigmentosa mutations.
objectiveThe current study aimed to determine the effect of 3',4'-Dihydroxyflavonol (DiOHF) supplementation for 1 week on lipid peroxidation in the retina tissue following focal brain ischemia-reperfusion in rats.
methodsThis study was carried out on male Wistar-albino rats. A total of 28 rats were used in the research, and four groups were formed: Control group: no anesthesia or surgical procedure was applied to the animals in this group, Sham group: after general anesthesia was established in the animals in this group, the carotid artery areas were opened and closed, and the 1 ml vehicle was applied for 1 week, Ischemia-Reperfusion (IR) group: after the carotid arteries were isolated in rats under general anesthesia, ischemia was performed by ligating them for 30 minutes, and then reperfusion was applied for 1 week, and Ischemia-Reperfusion + DiOHF group: under general anesthesia, ischemia was developed in the carotid arteries of the rats by ligation for 30 minutes, and then DiOHF was applied along with reperfusion for 1 week. At the end of the study, retinal tissue taken from animals sacrificed under general anesthesia was analyzed for MDA and GSH. Retinal tissue was also examined for histology and neurogenesis.
resultsThe highest MDA value was determined in the ischemia group, and the lowest value in the control and sham groups. In group 4, this parameter was found to be significantly lower than in the IR group. Retinal GSH was very low in the IR group. However, 1-week DiOHF treatment increased the GSH values. Deteriorations also occurred in the histological structure of the retinal tissue, and neurogenesis was inhibited. However, treatment improved retinal damage and neurogenesis.
conclusionThe results of the current study showed that focal brain ischemia in rats caused significant retinal lipid peroxidation. However, 1-week DiOHF treatment suppressed the increased lipid peroxidation by increasing GSH levels. Moreover, treatment improved retinal damage and neurogenesis.
Indexed as
Identifiers
39865828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.